Article

Low Entropy Sub-Networks Prevent the Integration of Metabolomic and Transcriptomic Data

Krzysztof Gogolewski *, Marcin Kostecki and Anna Gambin *

Institute of Informatics, University of Warsaw, 02-097 Warsaw, Poland; mrckostecki@gmail.com
*
Correspondence: k.gogolewski@mimuw.edu.pl (K.G.); aniag@mimuw.edu.pl (A.G.)

Received: 15 September 2020; Accepted: 27 October 2020; Published: 31 October 2020

Abstract: The constantly and rapidly increasing amount of the biological data gained from many different high-throughput experiments opens up new possibilities for data- and model-driven inference. Yet, alongside, emerges a problem of risks related to data integration techniques. The latter are not so widely taken account of. Especially, the approaches based on the flux balance analysis (FBA) are sensitive to the structure of a metabolic network for which the low-entropy clusters can prevent the inference from the activity of the metabolic reactions. In the following article, we set forth problems that may arise during the integration of metabolomic data with gene expression datasets. We analyze common pitfalls, provide their possible solutions, and exemplify them by a case study of the renal cell carcinoma (RCC). Using the proposed approach we provide a metabolic description of the known morphological RCC subtypes and suggest a possible existence of the poor-prognosis cluster of patients, which are commonly characterized by the low activity of the drug transporting enzymes crucial in the chemotherapy. This discovery suits and extends the already known poor-prognosis characteristics of RCC. Finally, the goal of this work is also to point out the problem that arises from the integration of high-throughput data with the inherently nonuniform, manually curated low-throughput data. In such cases, the over-represented information may potentially overshadow the non-trivial discoveries.

Keywords: genome-scale metabolic networks; information redundancy; metabolic landscapes analysis; graph entropy; renal cell carcinoma; transcriptomics

1. Introduction

Observing the technological progress of the recent decades one can notice that it facilitated an access to vast biomedical data resources describing different molecular levels (so-called -omics data). Consequently, our comprehension of biological processes becomes more profound as well as reliable. These facts open up a broad field of data integration, that aims to infer from various data collection platforms taking into account known biological dependencies between them.

Motivations. In the literature, it is broadly emphasized that the integration of -omics data improves understanding of various phenomena. The modern studies and corresponding literature emphasize the significant role of the integration of different -omics data types for better comprehension of a phenomenon of interest [1]. However, these integration procedures, thanks to a wider perspective, are not only meant to provide a new insight into a specific phenomena, but above all should constitute a deeper understanding of the general genotype-phenotype gap and the relationship between these two layers [2]. Importantly, each unique set of -omics data can be integrated using various statistical methods, and thus may result in an unprecedented outcome. As a consequence, each year a number of reviews are published to track and summarize the current state of the art in the field of -omics integration, which one can check for more detailed discussions [3,4].
In this work, however, the aim is to focus on a particular problem of the transcriptomic and metabolomic data integration. We report an interesting phenomenon related to the analysis of individual metabolic networks in the context of transcriptomic data. The conducted study allowed to detect a common and robust artificial pattern identifiable for each data cohort from the Cancer Genome Atlas that splits cancer-specific patients into two to four clusters. Interestingly, each cluster is characterized by a peculiar activity pattern among reactions hubs. In the article, we prove that these observations result mostly from the uneven metabolic information distribution within the metabolic network. To the best of our knowledge, no one has yet commented on the problem that the structure of a metabolic network can introduce when used along with integrative methods, in particular when used in the context of the flux balance analysis (FBA) [5].

Related research. One of the first attempts to this type of integration was suggested by Covert and Palsson, where authors infer the binary enzymatic activity from the transcriptomic continuous signal [6]. Next, a cascade of methods was proposed to harness transcriptomic data for analysis of metabolic networks. Among the most discussed methods we can point out: E-Flux [7], GIMME [8], GIMMEp [9], iMAT [10], INIT [11], MADE [12], mCADRE [13], PROM [14], RELATCH [15]. Apart from some minor details, fundamentally these approaches differ at three basic levels: (i) the way of inference of the enzymatic activity from transcriptomic data; (ii) the determination of the flow capacity boundaries from transcriptomic data; (iii) number of samples needed to create a mathematical model. These methods along with their other features, were already discussed and compared in few reviews where detailed descriptions can be found [16–19]. Therefore, here, we focus on a summary of what type of biomedical outcomes they have provided so far.

Using this type of models, where a general metabolic network becomes context-specific through integration with a transcriptome of specific tissue or organism few groups of researchers have already reported some interesting discoveries. With nearly 2000 samples of breast tumor Leoncikas et al. discovered a novel poor prognosis cluster characterized by local production of serotonin along with active extracellular matrix and membrane remodeling reactions [20]. Li et al. by integrating transcriptomic knowledge with human metabolic network suggest a supervised method to predict novel drug-target interaction [21]. In their work they predict related metabolic reactions and enzyme targets for approved cancer drugs, and predict drug targets with statistically high confidence rate. Reconstruction of a genome-scale metabolic models for 126 human tissues and cell types including healthy and tumor type was derived using the Recon 1 human metabolic network accompanied by transcriptomic data [13]. Among all, the set of models includes 26 tumour-specific models accompanied by their normal counterparts, in particular 30 models of brain tissue subtypes were determined. Next, using the modified version of iMAT, differential fatty acid uptake into mitochondria along with arachidonic acid and eicosanoid metabolism were suggested to explain different proliferative rates and invasiveness between PC-3/M (highly proliferative, cancer stem cells) and PC-3/S (highly invasive, epithelial-mesenchymal-transition-like properties) subpopulations derived from prostate cancer cell line [22].

In summary, the general biomedical aim of this approach is to model the gene–protein–reaction interactions in the form of a metabolic network and infer multiple biological properties, e.g., post-transcriptional gene activities or intensity and activity of metabolic reactions, that can explain the nature of analyzed sample.

Our results. In this paper, we want to draw attention to a specific problem related to the task of the data integration and analysis based on the general metabolic networks along with transcriptomic data. First, we present how the specific structure of sub-networks can inflate the importance of specific groups of enzymatic reactions, which may lead to incomplete or questionable conclusions. Next, in order to cope with that obstacle, we suggest a possible routine that can track and eliminate the unwanted problem influencing the metabolic knowledge obtained from the integration procedure. Furthermore, we present our results from the analysis of the TCGA renal cell carcinoma (RCC) dataset, which point out reactions discriminating patients in the context of the observed clinical
factors. Additionally, we report the discovery of a poor-prognosis cluster of patients along with its characterization. Finally, we point out and discuss some already existing methods of analysis of metabolic networks that are likely to be influenced by this subtle yet significant network structural property. The preliminary version of this study was published as an extended abstract in the proceedings of the 2018 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), pp. 96–101; Madrid, Spain.

2. Materials and Methods

2.1. The Human Genome-Scale Metabolic Reconstruction

In general, a metabolic network is a set of reactions among elements of a given set of metabolites. Each reaction may be associated with a specific genetic rule that needs to be met in order for reaction to occur. If a reaction has no genetic rule assigned to it, it can be triggered whenever all substrates are available. A genetic rule usually describes which genes/proteins need to be active/present in the system to carry out the reaction. In particular, a rule may require simultaneous presence of several enzymes (e.g., the transfer of L-Oh-Proline by the Apical Imino Amino Acid Transporters in Kidney and Intestine requires both Transmembrane Protein 27 and Solute Carrier Family 6), or alternative enzymes that can catalyze the reaction (e.g., efflux of 2-hydroxy-atorvastatin-lactone into bile that is supported by ATP binding cassette subfamily C member 2 or subfamily B member 1). Finally, each reaction has also a lower and upper bound describing minimal and maximal flow of metabolites through this reaction.

On the other hand, formally, the network can be considered as a Petri net with conditional transitions of places, where by a conditional transition we mean additional Boolean formula that needs to be met in order for transition to occur (see Figure 1 for the example).

| Activity | Reactions |
|----------|-----------|
| $G_1$: 0 | $R_1: M_1 + M_2 \xrightarrow{G_1 \lor G_2} M_4$ | $R_4: M_1 \xrightarrow{G_2} M_3 + M_4$ |
| $G_2$: 1 | $R_2: M_3 \xrightarrow{G_1} M_2$ | $R_5: M_4 \xrightarrow{T} M_1$ |
| $G_3$: 1 | $R_3: M_1 \xrightarrow{G_1 \land G_2} M_2$ | $R_6: M_3 + M_4 \xrightarrow{G_1 \land G_3} M_5$ |

**Figure 1.** An example of metabolic network with genetic rules. The example is composed of six reactions $R_i$ among five metabolites $M_j$. Among these reactions there are five enzymatic reactions that are coordinated by the enzymes related to the three specific genes $G_k$. All arrows describe the flow of metabolites through reactions according to the above list of reactions. Using the gene activity pattern, a general network can be turned into transcriptom specific and represented as a Petri net with conditional transactions. Here we can see that inactivity of gene $G_1$ results in silencing (dotted line) of the reactions $R_3$ and $R_6$ which represses the production of the metabolite $M_2$ and eliminates the production of the $M_5$ in the system.
In our study we used the human genome-scale metabolic reconstruction model, RECON 2.2 that details known metabolic reactions occurring in humans, and thereby holds substantial promise for studying complex diseases and phenotypes [23]. The model described 7785 reactions (i.e., transitions of a Petri Net), between 2654 metabolites (i.e., places), out of which 4742 depended on a genetic rule (i.e., condition of a transition). We will refer to these reactions as enzymatic reactions. Each genetic rule was a Boolean formula in a disjunctive normal form (DNF), where each Boolean variable corresponds to the activity state (active or not) of one of 1670 unique genes. Additionally, all of the metabolites in the network were distributed among 10 compartments. In total, we considered 6048 compartment-specific metabolites. For more details see Table 1 and Figure 2.

2.2. Metabolic Landscapes

In order to construct a sample-specific metabolic model from a general metabolic network given a transcriptomic pattern the following procedure was applied. First, we specified the thermodynamic conditions describing the acceptable capacity of reactions fluxes, i.e., set the minimal and the maximal flow levels through each reaction. Next, we evaluated each genetic rule, based on the transcriptomic data to decide which reactions could occur in the initial model (see an example in Figure 1). Finally, the obtained, individualized model could be further studied taking into consideration the metabolic network structure. In our work, the linear programming problem was formulated and the simplex algorithm was run to find the steady-state flux distribution. This procedure provided two types of information. First, it suggested a new pattern of fulfillment among the genetic rules (binary-valued), where each change, in contrast to the original value, could be considered as a post-transcriptional change. Second, it outputted a vector of fluxes that met the criteria of the linear problem that was solved. These fluxes could provide information about the metabolic reactions or pathways that were mostly exploited given such expression patterns.

| Table 1. The table provides a summary of the RECON 2.2 metabolic model. |
|-----------------|-----------------|-----------------|
|                  | enzymatic       | transport       |
| all reactions    | 7785            | 4742            |
| exchange        | 701             |                |
| demand          | 44              |                |
| reverse         | 3782            |                |
| directed        | 4003            |                |
| all metabolites  | 6048            |                |
| unique substances| 2654            |                |
| boundary        | 722             |                |
| compartments    | 10              |                |
| all genetic rules| 4742            |                |
| simple rules    | 2912            |                |
| complex rules   | 1830            |                |
| unique rules    | 1341            |                |
| unique genes    | 1670            |                |

* Exchange reactions describe in- and outflow of metabolites through the system boundary. * Demand reactions are intra-network, unlimited sinks or sources of metabolites degradation or production. * An additional metabolite (in contrast to the summary reported in [23]) was required for the R_biomass_other reaction.
Figure 2. The figure presents an outline of the reactions distribution in the metabolic model of RECON 2.2. There are nine inter-cellular compartments depicted and the additional boundary component which represents external entry and exit of metabolites into the metabolism network model. Each line connecting two compartments represents all reactions that involve metabolites from these compartments. The number of these reactions and their direction is assigned to each line. To keep the figure readable, for less than 10 reactions we use a dotted, thinner line.

2.3. TCGA Transcriptomic Data

In this study we used 20 RNA-seq transcriptomic datasets provided by TCGA, each composed of cancerous and control samples and accompanied by clinical data. For the purpose of our work, each dataset was subjected to a standard preprocessing routine with recount R package [24]. The raw counts were scaled by the total coverage of the sample, that is, the area under the curve (AUC) of the coverage. Next, only genes that were composing genetic rules in the RECON 2.2 model were selected. Finally a number of 5 read counts was selected to be a threshold for a gene to be considered as active. After Leucken et al. the thresholding procedures were as permissive as possible, so that downstream analysis could be conducted and interpreted [25].

In the presented case study we used the kidney cancer dataset (renal cell carcinoma, RCC) composed of the 897 primary tumor and 129 normal tissue samples. Tumor tissues were also classified by their morphological type subtype into four groups: 527 clear cell RCC, 290 papillary RCC, 66 chromophobe RCC and 14 unclassified RCC samples. For 201 patients the survival data were also available. Additionally, we used the brain cancer dataset (707 samples) to showcase the artifacts of the clustering results obtained from the metabolic landscapes.
2.4. Steady-State Flux Distribution

In order to determine the activity state of each reaction in a personalized model we made use of the approach proposed by Shlomi et al. [26]. We formulated a mixed-integer linear programming (MILP) problem (see Equation (1)) and solve it using Gurobi solver [27]. The goal was to maximize an objective function (1a) with respect to stoichiometric (1b), thermodynamic (1c) and transcriptomic (1d–g) constraints. For detailed description see the Methods section in [26].

The solution of the described problem provided a binary vector of activity states for each reaction which we refer to as a metabolic landscape.

\[
\begin{align*}
\max_{v, y^+, y^-} & \quad \sum_{r \in A} (y^+_r + y^-_r) + \sum_{r \in I} y^+_r \\
\text{s.t.} & \quad S \cdot v = 0 \quad & (b) \\
& \quad v_{\min} \leq v \leq v_{\max} \quad & (c) \\
& \quad v_{\min,r} (1 - y^+_r) \leq v_r - y^-_r \quad & r \in A \quad (d) \\
& \quad v_{\max,r} (1 - y^-_r) \geq v_r + y^-_r \quad & r \in A \quad (e) \\
& \quad v_{\min,r} (1 - y^-_r) \leq v_r \quad & r \in I \quad (f) \\
& \quad v_{\max,r} (1 - y^-_r) \geq v_r \quad & r \in I \quad (g) \\
& \quad v \in \mathbb{R}^m, \quad y^+_r, y^-_r \in \{0, 1\}
\end{align*}
\]

In the described setting the FBA problem was formulated as a linear program and solved using the simplex algorithm. However, it should be emphasized that the structure of the underlying graph was crucial in context of the flux analysis and the existence of dense sub-graphs loosely communicating with neighbouring vertices strongly influenced the final outcome of the algorithm.

2.5. Graph Entropy

To detect the possible sources of the structural redundancy in a metabolic network we applied the measure of entropy on a graph structure. To account for the context of the metabolic fluxes we made use of the entropy based on the inner and outer neighbours of vertices within a given sub-graph [28].

Namely, for a graph \( G = (V, E) \) and its sub-graph \( G' = (V', E') \) where \( V' \subset V \) and \( E' \subset E \) contains all edges adjacent to vertices in \( V' \) we define the probability of the inner (\( P_I \)) and outer (\( P_O \)) flow of a vertex \( v \in V' \) as:

\[
P_I(v) = \frac{I(v)}{N(v)}; \quad P_O(v) = \frac{O(v)}{N(v)} = 1 - \frac{I(v)}{N(v)}
\]

where \( I(v) \), \( O(v) \) are the number of neighbours of \( v \) that: belong to \( V' \) and not belong to \( V' \), respectively, while \( N(v) \) are all neighbours of \( v \). Based on that we define the entropy \( H(v) \) of a vertex \( v \) as:

\[
H(v) = -P_I(v) \log_2 P_I(v) - P_O(v) \log_2 P_O(v)
\]

and consequently, the entropy of a graph \( G \) induced by sub-graph \( G' \), \( H_{G'}(G) \), is defined as:

\[
H_{G'}(G) = \sum_{v \in V'} H(v)
\]

Given the above definitions, we determine the entropy of a group of enzymatic reactions within the RECON 2.2 metabolic network. Additionally, we evaluate the entropy induced by groups of random reactions sampled from the entire network. These steps aim to depict the graph in terms of the entropy and thus connectivity and the flow of metabolic information, that is subject to the metabolic landscape analysis.
2.6. Binary Data Analysis

Since the final outcome of a linear programming problem is a set of binary vectors, it is necessary to introduce specific methods to analyze them. In the literature there are described various statistical methods that are specifically dedicated to the analysis of binary data, including: the non-negative matrix factorization [29], the sparse logistic PCA method proposed by Lee et al. [30], and the variational factorization method employing independent beta latent densities [31].

Nonetheless, in our case, in order to explore the data, track the potential latent variables and visualize results we use the standard principal component analysis (PCA), which provides numerically stable and robust results and is also used to define a function for separating variables selection.

PCA Loadings-Based Variables Selection

Let $M \in \{0, 1\}^{m \times n}$ be a binary data matrix with $m$ observations and $n$ variables, $L = (L^{(1)}, \ldots, L^{(n)})$ be a loadings matrix and $P$ scores (or principal components) matrix, satisfying $P = ML$. By definition $P$ is a representation of $M$ in a new basis that is composed of vectors of $L$. For the purpose of binary landscapes analysis, we construct a set of highest valued coordinates from first $k$ directions of the rotation matrix. The general parametrized function $L$ describes the selection procedure:

$$L_{f,k}(L) = \bigcup_{i=1}^{k} \{ j : |L^{(i)}_j| \geq f(L^{(i)}) \}$$

where $f$ is the function determining the threshold for the value of a coordinate to be assumed significant and $k$ is the number of vectors from loading matrix that are considered. The function is used to select the groups of reactions with the highly correlated activity pattern between all samples. In parallel, the results from PCA Loadings-based variable selection were compared with the overall entropy analysis of the network structure considering the interaction between the groups of enzymatic reactions. It turned out that the groups requiring the adjustment belong to the group of clusters characterized by the low entropy and loosely connected to the other vertices in the network.

To determine differentiating variables in the studied datasets, two measures were used. First, the Jaccard Index is used to determine differentiating reactions between two groups of samples. For any $z \in \{0, 1\}^n$ we define $z^1 = \sum_i z_i$ and $z^0 = \sum_i (1 - z_i)$. Given that the Jaccard Index of two binary vectors $J : \{0, 1\}^n \times \{0, 1\}^m \rightarrow [0, 1]$ is defined as:

$$J(x, y) = \frac{\min (x^1, y^1) + \min (x^0, y^0)}{\max (x^1, y^1) + \max (x^0, y^0)}$$

The index is non-linear and depends on the lengths of vectors, thus evaluates to 0 when two vectors don’t share any element, increases with an increasing number of shared elements between vectors. It reaches the maximal value of 1 when both vectors share the same elements and the same lengths. In the process of variables selection as a threshold value we set 0.25 of the maximal value that the index can reach (given the lengths of compared vectors).

Additionally, the Tanimoto similarity measure of two binary vectors $T : \{0, 1\}^n \times \{0, 1\}^n \rightarrow [0, 1]$ is defined as:

$$T(x, y) = \frac{n - |\{i : x_i \neq y_i\}|}{n + |\{i : x_i \neq y_i\}|}$$

and is used as a distant measure between two binary metabolic landscapes.
3. Results

3.1. Metabolic Network Structure Problems

The first step was to apply the procedure suggested by Shlomi et al. to the cohort of the TCGA data in order to verify if there existed a common metabolic pattern among various types of tumors, or alternatively, if there existed any metabolic biomarkers which may be of diagnostic importance. As mentioned in the introduction, our preliminary results suggested that, surprisingly, each data set was composed of two to four clearly separable clusters of patients. In the case of 13 out of 20 TCGA cancer datasets, the corresponding set of metabolic landscapes was well-separated into four clusters that, on average, were differentiated by the activity of 180 reactions. Additionally, for the remaining seven cancer-specific landscape datasets there were on average 95 reactions differentiating samples into two clusters (see Figure 3 for an example based on brain cancer dataset). Moreover, it turned out that almost all (>95%) discriminating (using $L_{max}^2$ function) reactions in these clusters were coordinated by two main enzymes that were encoded by: SLCO1A2 (solute carrier organic anion transporter family member 1A2; coordinating superfamily of 94 Amino Acid-Polyamine-Organocation reactions [32]) and SLC7A9 (solute carrier family 7 member 9; coordinating superfamily of 79 Resistance-Nodulation-Cell Division reactions [33]) genes. These observations may lead to a conclusion that cancers in general have natural subfamilies that can be described by the activity of specific groups of metabolic reactions and thus also activity of particular enzyme encoding genes. Activation of SLCO1A2 is related to the development and functioning of the immune system, organismal system for calibrated responses to potential internal or invasive threats and is highly over expressed in breast cancer tissues [34]. On the other hand, SLC7A9 enables the transportation of substances (such as macromolecules, small molecules, ions) into, out of or within compartments of a cell, or between cells. Additionally, as a co-enzyme with SLC3A1 coordinates group of five transportation/exchange reactions of L-Cystine, L-Alanine and L-Ornithine, that were also detected as differentiating the cancer data. This observation implies activation of SLC3A1, that was recently reported to promote breast cancer tumorigenesis [35].

Even though these literature reports may sound promising, we report another observation related to the analysis performed on a dataset with 500 randomly generated gene activities that were subjected to the metabolic analysis (see the right panel of the Figure 3). Despite the fact that the gene activity dataset did not include any relevant information, we were able to identify two groups of reactions differentiating samples into four well-separable clusters. These observations, undoubtedly, put in question all results related to the clustering of metabolic landscapes performed on all cancer datasets, since the analysis inferred about the knowledge that did not come from the data but from the topology and structure of metabolic network.

The analysis of the RECON 2.2 network structure revealed that there existed groups of reactions that were associated with the same genetic rule (top 10 most common genetic rules were related to over 900 reactions). Even though these reactions were biologically non-redundant (each of them was functional), they very often formed well-connected sub-networks that were loosely connected with the rest of the network. As a consequence they made it problematic to apply the FBA methods. As the way to identify such structures we proposed to apply the notion of entropy induced by sub-networks. It turned out that these sub-networks minimized the entropy.

In the Figure 4 one can notice the structural properties of the RECON 2.2 metabolic network. We discovered that among the groups of enzymatic reactions that follow the same genetic rule, there was a representation of these that consisted of several dozen of reactions and yet induced a very low entropy of the sub-network. The entropy- and structural-based analysis revealed that these reactions were very well connected within their group, however they were loosely connected to the neighbouring vertices outside their group. Such characteristics imposed the risk of the uneven flow of the metabolic information throughout the network and made it of low probability that initial transcriptomic conditions would be changed due to the influence of the other neighboring reaction
states. In effect, this may result in the detection of network topology artifacts rather than new information on metabolic reactions.

For this reason we proposed two adjustment methods that take into account this phenomena. The aim was to transform the data so that the statistical analysis did not detect artificially induced data separation, but rather may result in a discovery of subtle differences in metabolic activity between samples possibly related to novel metabolic biomarkers.

3.2. Computational Workflow

Due to the discovery of the artifacts in the results of the metabolic landscape analysis we propose the following pipeline of procedures, that aims to reduce the statistical redundancy immersed in the RECON 2.2 network structure.

As the prerequisite, the entropy levels of each group of enzymatic reactions are determined with the tools described in the Materials and Methods section. These are the base of the control for redundant activity patterns in the statistical inference from the reaction activities.

First, we processed the RNA-seq transcriptomic data and converted it to the gene activity matrix using the threshold of five counts. The matrix was then used to create a personalized metabolic network model. For each of these, a MILP problem was formulated and solved with the Gurobi solver based on the simplex algorithm. The solution was composed of the sample-specific metabolic landscapes, which were subjected to statistical analysis. The analysis of the data was supported by the two-fold verification if the redundancy among groups of reactions existed. On one hand, using the PCA loadings-based variables selection $L$ function defined in the subsection Binary Data Analysis, on the other assessing the entropy of the detected group of reactions. Based on these two conditions, if needed, the adjustment of these reactions was performed.
Figure 4. The entropy levels induced by specific sub-networks in RECON 2.2 by their size. The upper panel depicts the entropy level induced by each sub-network of enzymatic reactions following the same genetic rule (the blue area and outlying blue points). The grey area shows the entropy levels for random groups of reactions of a given size. The groups of reactions that characterize the RCC samples before and after the adjustment, as well as, the potential biomarker reactions for the discovered poor-prognosis cluster are depicted by corresponding points. The bottom panel is a close-up view of the low-number groups of reactions.

The data transformation was based on the aggregation of the activity states for groups of reactions with respect to compartments to which belong their substrates and products. Namely, each reaction was labeled with a name of form $s_1 \ldots s_k - p_1 \ldots p_j$, where $s_1, \ldots s_k$ and $p_1, \ldots, p_j$ are alphabetically ordered names of compartments that, respectively, substrates and products belonged to. Next, all reactions with the same genetic rule and the assigned label were aggregated into the one represent reaction with the level of activity equal to the average of activities in the group.

Finally, inference from the transformed data structure through the hierarchical clustering using the binary distance measures (e.g., the Tanimoto similarity), correlation with the clinical data, selection of discriminatory features and functional analysis of determined clusters was performed. The outline of the described workflow is also depicted in the Figure 5. Additionally, in the Github repository: https://github.com/storaged/metabolic-landscape the code and the scripts used in this workflow are available. For the purpose of this study the workflow was executed on the machine with Mac OS.
3.3. Metabolic Landscape Adjustment for the Renal Cell Carcinoma

In order to validate the proposed workflow we performed the metabolic landscape analysis on the TCGA dataset of renal cell carcinoma (RCC). After performing the adjustment methods on the metabolic landscapes we reported a significant improvement in samples clustering, both in the sense of unwanted network structure-dependent clusters composition and correlation with clinical data (see Figure 6). Additionally, we took advantage of the provided prerequisite and confirmed that all of the adjusted groups of reactions fell into the group of the low-entropy level (see Figure 4).

We removed the amplified activity pattern of reactions coordinated by the same genetic rule, that influenced the clustering of samples in an unwanted way. After the reduction there were no significant, discriminating reactions associated with the same genetic rule. This step also resulted in more reliable clustering of data according to clinical observations, e.g., normal or tumor tissue type or morphological type of a tumor sample.

The results of our analysis of the renal cell carcinoma TCGA dataset were consistent with latest reports, that indicated SLC6A3 as a experimentally confirmed biomarker for RCC [36].
The transcriptomic signal of SLC6A3 in our data was clearly discriminating biomarker of Clear Cell RCC subtype (6.89 logFC).

However, thanks to the analysis of metabolic landscapes we further suggest potential biomarkers that correspond to specific, known RCC subtypes [37]. The literature so far reports CXCL16 gene as a significantly expressed in papillary RCC with others still waiting for their validation [38]. Nonetheless, the analysis of metabolic landscapes suggests two transport reactions that discriminate the Papillary RCC subtype. Both of them are supported alternatively by the already reported SLC6A3 or SLC6A2, other member of the same Solute Carrier family. The transportation activity state of dopamine and norepinephrine via sodium symport between cytoplasm and extracellular space are well separating the Papillary RCC subtype from other samples. Namely, these reactions are predicted to be inactive in Papillary samples. Our results reported 247 out of 291 (≈85%) papillary samples and 42 out of 737 (≈6%) other samples characterized by inactivation of these reactions. This observation was also confirmed by the purely transcriptomic data, which suggested down regulation of both genes (−3.62 and −2.2 logFC of SLC6A2 and SLC6A3, respectively) for papillary samples. This observation suggested a simultaneous drop of the activity of both SLC6A2 and SLC6A3 as a potential diagnostic biomarker.

In case of the Chromophobe RCC (ChRCC) subtype, before the adjustment of the metabolic landscapes two genetic rules were in fact separating this subtype from the other cancer samples: (i) the extracellular space and cytoplasm exchange reactions supported by the complex of SLC3A1 and SLC7A9 (five reactions involving L-Cystine, L-Alanine and L-Leucine) and (ii) reactions controlled by SLC7A9 that was involved in 79 reactions. However, after the adjustment two potential biomarkers were found: inactivation of sodium-dependent transport of (i) phosphate, supported by SLC17A1 and (ii) ascorbate supported by SLC23A1. Inactive phosphate and ascorbate transport characterized, respectively, 65 and 62 out of 66 ChRCC samples; 45 and 28 out of 774 other tumor samples. Even in the literature reports it is still not clear how the phosphate transportation or concentration level and absorption via SLC23A1 of ascorbate influences the cancer cells [39]. We point to these factors, both reaction activity and transcriptomic/proteomic levels, as possible biomarkers of ChRCC.

### 3.4. Poor Prognosis Cluster

Finally, we reported a candidate for a new cancer subtype resulting from the statistical and functional analysis of metabolic landscape clusters. Based on the samples clustering after the adjustment (see Figure 6) we further studied the obtained six clusters of samples. Among them, there were four homogeneous clusters composed mainly of: the healthy tissues (Control), the Chromophobe RTCC subtype (Chr-basal), the Clear Cell RTCC (CC-basal) and the Papillary RTCC (Pap-basal). Even though, the pattern of the remaining two clusters was not related to their morphological type we noticed a statistically significant (p-value: 0.002) difference in the survival time in one of the clusters (see Figure 7), which we addressed as a poor prognosis cluster.

The first and natural step here is to compare our clustering with the previously published [40]. In particular, the membership of the CpG island methylator phenotype (CIMP) cluster is of high interest, because of its bad prognosis properties that were investigated in [41]. It turns out that the entire CIMP cluster was part of the much larger (10 vs. 102) poor prognosis cluster that was identified based on its metabolic profile. Additionally, our poor prognosis cluster also contained five out of six samples classified as metabolically divergent (MD) in the literature. While CIMP-associated tumors showed increased expression of key genes involved in glycolysis, our cluster metabolic pattern was also associated with deregulations in glycan biosynthesis. However, the important characteristic feature was the reduced expression of genes related to amino acid transport.
Figure 7. The analysis of the poor prognosis cluster. The heatmap presents the activity of reactions from the four clusters determined with the hierarchical clustering. The upper horizontal stripes compare the predicted subtypes (PS) labeling with the known morphological types (MT). The bottom-left panel presents the Kaplan–Meier survival curves, which present the significantly lower survival time of patients from the poor prognosis cancer ($p$-value: 0.002). The bottom-right panel compares the expression level of the genes characterizing the poor prognosis cluster.
To deepen the nature of these newly discovered clusters, we performed a differential analysis of four clusters (using also CC-basal and Pap-basal) in order to describe a metabolic as well as genetic nature of this cluster. We determined a set of 106 differentiating reactions coordinated by four genes: \textit{OAT2} (3), \textit{PRODH2} (4), \textit{PKLR} (5) and \textit{SLC1A2} (94), see Figure 4. Among these reactions we report orotate-glutamate antiport, uptake of allopurinol and oxypurinol by the hepatocytes, mitochondrial proline Oxidase (NAD) and dehydrogenase, and reactions involved in pyruvate metabolism. Genes coordinating these reactions reveal a specific expression pattern of the poor prognosis cluster, i.e., the low expression and the consequent inactivation of corresponding reactions. It is worth to emphasize, that the adjustment procedure provides a confirmation of the significance of the hub of reactions governed by the \textit{SLC1A2} gene (see the corresponding datapoint in the Figure 4).

Additionally, we performed the functional analysis of top 100 differentiating genes, using the DAVID on-line tool. The analysis provided a consistent output indicating functions and keywords commonly related to modifications in transport and symport reactions highlighting transmembrane transport activity. Finally, pathway analysis performed with KEGG implied deregulations in the glycan biosynthesis and metabolism pathway.

The above observations can be preliminarily verified with literature reports. In a metabolic sense, abnormalities in glycan biosynthesis that we observe were reported as a significant factor of cancer cells phenotype and biology almost two decades ago [42]. It should be emphasized that recent studies stress the particular role of amino acid transporters in the pathogenesis of cancer. Specifically, the deregulation of these genes leads to metabolic reprogramming changing intracellular amino acid levels, which may underlie the molecular processes that explain poor prognosis in detected cluster [43]. Moreover, in our study, the poor prognosis properties can be influenced by the low activity of \textit{SLC1A2} belonging to the organic-anion-transporting polypeptide (OATP) family, because it is responsible for transport of anticancer drugs (e.g., methotrexate used in chemotherapy) [44] and overall uptake of. Similarly, low expression of \textit{OAT2} was reported to influence a poor response to antitumor UFT-based chemotherapy in colorectal cancer patients [45]. Loss of \textit{PRODH2} was also reported in cancer [46], however no links with cancer prognostics were reported. The above summary may constitute an introductory justification for the possible existence of the poor prognosis cluster in RCC mainly conditioned by the chemoresistance dictated by the activity of its potential biomarker genes.

4. Discussion and Further Research

Concluding, in our article we recall an important yet barely discussed data analysis and integration problem of the two-fold nature. Using the TCGA datasets and the metabolic network model we presented how the bioinformatic and statistical data analysis may lead to outwardly interesting biological and medical observations, which may be justified by the literature reports. However, not only do we prove that these observations are the inevitable consequence of the model assumptions (as genetic rules induce clusters artificially), but also we show that these assumptions conceal the current state of knowledge about cell metabolism, as many discovery claims may testify.

We believe that the identified problem is important enough to look at alternative approaches and verify if they are not exposed to the similar obstacle. However, as it was already mentioned, there is a strong evidence that the problem highlighted in this work may be present in other researches that dealt with the analysis of the FBA outcome. The reason, even though is very subtle, is related to the linearity of the solving method applied to the non-linear topology of the problem support. In particular, the existence of internally strongly connected sub-graphs that are loosely connected with their neighbouring vertices influences the graph flow approaches. The metabolic information cannot be flawlessly passed on between reactions and thus interferenced by particular information-flow blockers. Here, we briefly discuss several alternative approaches as an extension to the literature overview presented in the Introduction.
To the scope of the traditional linear programming approach to solve the FBA problem we add what Lee et al. proposed in their work. The redefinition of the main objective function as well as an emphasis put on the more informative nature of absolute gene expression measurements provided by RNA-seq data was presented. Authors set an optimization problem to maximize the correlation between an observed transcriptomic profile and levels of reactions fluxes, that is solved using the MILP solver. Authors provide a case study based on estimation of exometabolic flux in *Saccharomyces cerevisiae* and show that their method outperforms the traditional approach upon maximisation of the rate of biomass production.

Additionally, there is also a bunch of approaches that extends the approach to the FBA problems onto the field of Bayesian statistics. One example of an extension of the FBA via Bayesian factor modeling was suggested by Angione et al. [47]. The extension bases on an assumption that high-dimensional data are generated from the hidden lower-dimensional factors that are shared across data samples. As a consequence, as a first step authors solve the bi-level FBA problem, which extends the standard problem by interdependencies among enzymes and genetic rules coordinating metabolic reactions. Next, Bayesian matrix factorization modeling with Gaussian Markov random field is incorporated to perform pathway analysis that takes into account reaction-pathway memberships as prior knowledge. Using a metabolic model of *Escherichia coli* authors present how their model tracks changes in pathway responsiveness for various experimental conditions.

Lately, in [48] authors presented an approach that results in flux posterior represented as an unimodal truncated multivariate normal (TMVN) distribution. Using a MCMC Gibbs sampler implemented in Matlab a group of in-silico experiments was performed to highlight the capabilities of the model. The presented approach allows to characterize the genome-scale flux covariances, reveal flux couplings, and determine genome-scale number of intracellular unobserved fluxes in *Clostridium acetobutylicum* from 13C data based on a small set of intracellular flux measurements.

Interestingly, the problem of flux estimation was also approached from the perspective of the thermodynamic analysis. Zhu et al. introduce a novel, two-step optimization method termed as thermodynamic optimum searching [49]. First, the original FBA is used to determine the maximum growth rate. Then, the most thermodynamically favored solution is acquired by solving a nonlinear optimization problem in which the growth rate is fixed to the maximum. The later aim is achieved by maximizing the entropy production rate while minimizing energy usage and deviation from the second law of thermodynamics related to the the minimum magnitude of the Gibbs free energy change and the maximum entropy production principle. The method is supported with five *E. Coli* case studies presenting the improved accuracy of predictions compared to the standard FBA.

What should be emphasized here is that none of the recalled articles mentioned any observation on the relationship between the structure of the metabolic network and their final outcome. Additionally, an alarming fact is the use of methods such as the categorization of the transcriptomic signal, linear (or semi-linear) methods of solving the flow problem, binarization of data and their interpretation based by clustering. All of these observations allow the reader to ask if any control for artifacts was performed. In order to compare the methods, approaches, objectives of all the mentioned works in this article a table summary is provided in the Appendix A.

To conclude, the future directions in which we would like to conduct this research include incorporating other metabolic networks for the landscape analysis, but also improved adjustment methods, that would define and take into account the confidence of the reaction. One idea in that direction, would be to incorporate some experimental validations from the literature reports. Ideally, we would like to reach the gold standard using measurements from the 13C-fluxomics technology, where metabolic precursors enriched with 13C and quantified by mass spectrometry or NMR [50,51], as well as from transcriptomic assays. However, such data has so far been collected for relatively small systems, e.g., single pathways [52] or other simple organisms [53], while our amendment concerns the whole human cell metabolism. Another option is to take into account the entropy-based approach and propose a sample-specific adjustment method. Finally, we also suggest
defining a probability of reaction activity, that may be introduced instead of currently considered binary activity state. This would allow to make use of the continuous information included in the expression data, rather than reduced binary signal. We believe that these improvements may lead to better understanding of cancer biology and phenotype resulting from the observed differences in metabolic activity.

**Author Contributions:** The individual contributions of each author of this article presents as follows: conceptualization, K.G., M.K. and A.G.; methodology, K.G.; software, K.G. and M.K.; validation, K.G. and M.K.; formal analysis, K.G.; data curation, K.G.; writing—original draft preparation, K.G. and A.G.; visualization, K.G.; supervision, A.G.; project administration, A.G.; funding acquisition, A.G. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research and APC was funded by the polish National Science Centre (NCN) grant no. 2014/12/W/ST5/00592.

**Acknowledgments:** Authors thank to the doctoral studies program funded by NCBR (The National Centre for Research and Development, Poland) project Descartes.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

The following abbreviations are used in this manuscript:

- ATP: Adenosine Triphosphate
- ChRCC: Chromophobe Renal Cell Carcinoma
- DAVID: Database for Annotation, Visualization, and Integrated Discovery
- DNF: Disjunctive Normal Form
- FBA: Flux Balance Analysis
- LP: Linear Programming
- MCMC: Markov Chain Monte Carlo
- MILP: Mixed-Integer Linear Programming
- PCA: Principal Components Analysis
- RCC: Renal Cell Carcinoma
- RNA: Ribonucleic Acid
- TCGA: The Cancer Genome Atlas
- TMVN: Truncated Multivariate Normal

**Appendix A**

A literature search of articles was conducted, and Table A1 summarizes and compares the literature and research that was related to the FBA problem and integration of the transcriptomic and metabolic knowledge. Let us emphasize that nearly each objective in the presented works is related to detection of activation profiles. Yet, artifact detection is not considered in any of the articles.
Table A1. Summary of the literature related to the problem of integrating the transcriptomic and metabolomic in the context of the flux balance analysis (FBA) problem.

| Author                     | Approach          | Software | Data Used                          | Objective                                      | Problem Size                                      |
|----------------------------|-------------------|----------|------------------------------------|------------------------------------------------|----------------------------------------------------|
| Leoncikas et al. (2016) [20] | MILP              | R(−)     | microarray detection p-value       | activity of flux states in a network           | 3311 reactions, 2766 metabolites, 2004 genes       |
| Li et al. (2010) [21]       | reduced MILP      | Matlab(−) | gene expression of NCI-60 cancer cell lines | reaction flux and activity for all the reactions | 3742 reactions, 2766 metabolites, 1905 genes       |
| Wang et al. (2012) [13]     | Model Building Algorithm | Matlab(+) | gene expression or literature evidence | activity for all the reactions                 | 3311 reactions, 2766 metabolites, 2004 genes       |
| Marín de Mas et al. (2018) [22] | MILP              | FASIMU(+) | microarray transcriptomic data     | activity for all the reactions                 | 3311 reactions, 2766 metabolites, 2004 genes       |
| Mhamdi et al. (2020) [54]   | Bayesian          | -        | RNA-seq data                       | prediction of the biomass production          | 4008 reactions, 3292 metabolites                   |
| St. John P. C. et al. (2019) [55] | Bayesian       | Python(+) | metabolite, boundary flux, enzyme measurements [56] | infer posterior distributions in kinetic parameters of a metabolic network | 203 metabolites, 240 reactions                     |
| Heinonen et al. (2019) [48] | Bayesian          | Matlab(+) | metabolic networks                | find posterior probabilities of fluxes states in a network | 4388 reactions, 2936 genes                         |
| Angione et al. (2015) [47]  | semi-Bayesian     | Matlab(+) | microarray expression profiles     | detect pathway cross-correlations and predict metabolic pathway activation profiles | 2583 reactions, 466 genes                         |
| Heino et al. (2007) [57]    | Bayesian          | Matlab(−) | ischemic biopsy data [58]          | find posterior probabilities of fluxes states in a network | 26 reactions, 53 metabolites                       |
References

1. Huang, S.; Chaudhary, K.; Garmire, L.X. More Is Better: Recent Progress in Multi-Omics Data Integration Methods. *Front. Genet.* 2017, 8, 84. [CrossRef] [PubMed]

2. Gjøysland, A.B.; Vik, J.O.; Beard, D.A.; Hunter, P.J.; Omholt, S.W. Bridging the genotype-phenotype gap: What does it take? *J. Physiol.* 2013, 591, 2055–2066. [CrossRef] [PubMed]

3. Wanichthanarak, K.; Fahrmann, J.F.; Grapov, D. Genomic, Proteomic, and Metabolomic Data Integration Strategies. *Biomark. Insights* 2015, 10, 1–6. [CrossRef] [PubMed]

4. Fondi, M.; Lio, P. Multi-omics and metabolic modelling pipelines: Challenges and tools for systems microbiology. *Microbiol. Res.* 2015, 171, 52–64. [CrossRef] [PubMed]

5. Orth, J.D.; Thiele, I.; Palsson, B. What is flux balance analysis? *Nat. Biotechnol.* 2010, 28, 245–248. [CrossRef]

6. Covert, M.W.; Palsson, B. Transcriptional regulation in constraints-based metabolic models of Escherichia coli. *J. Biol. Chem.* 2002, 277, 28058–28064. [CrossRef] [PubMed]

7. Colijn, C.; Brandes, A.; Zucker, J.; Lun, D.S.; Weiner, B.; Farhat, M.R.; Cheng, T.Y.; Moody, D.B.; Murray, M.; Galagan, J.E. Interpreting expression data with metabolic flux models: predicting Mycobacterium tuberculosis mycolic acid production. *PLoS Comput. Biol.* 2009, 5, e1000489. [CrossRef]

8. Becker, S.A.; Palsson, B.O. Context-specific metabolic networks are consistent with experiments. *PLoS Comput. Biol.* 2008, 4, e1000082. [CrossRef]

9. Bordbar, A.; Mo, M.L.; Nakayasu, E.S.; Schrimpe-Rutledge, A.C.; Kim, Y.M.; Metz, T.O.; Jones, M.B.; Frank, B.C.; Smith, R.D.; Peterson, S.N.; et al. Model-driven multi-omic data analysis elucidates metabolic immunomodulators of macrophage activation. *Mol. Syst. Biol.* 2012, 8, 558. [CrossRef] [PubMed]

10. Zur, H.; Ruppin, E.; Shlomi, T. iMAT: An integrative metabolic analysis tool. *Bioinformatics* 2010, 26, 3140–3142. [CrossRef]

11. Agren, R.; Bordel, S.; Mardinoglu, A.; Pornputtapong, N.; Nookaew, I.; Nielsen, J. Reconstruction of genome-scale active metabolic networks for 69 human cell types and 16 cancer types using INIT. *PLoS Comput. Biol.* 2012, 8, e1002518. [CrossRef]

12. Jensen, P.A.; Papin, J.A. Functional integration of a metabolic network model and expression data without arbitrary thresholding. *Bioinformatics* 2011, 27, 541–547. [CrossRef]

13. Wang, Y.; Eddy, J.A.; Price, N.D. Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. *BMC Syst. Biol.* 2012, 6, 153. [CrossRef] [PubMed]

14. Chandrasekaran, S.; Price, N.D. Probabilistic integrative modeling of genome-scale metabolic and regulatory networks in Escherichia coli and Mycobacterium tuberculosis. *Proc. Natl. Acad. Sci. USA* 2010, 107, 17845–17850. [CrossRef]

15. Kim, J.; Reed, J.L. RELATCH: Relative optimality in metabolic networks explains robust metabolic and regulatory responses to perturbations. *Genome Biol.* 2012, 13, R78. [CrossRef] [PubMed]

16. Mardinoglu, A.; Nielsen, J. Systems medicine and metabolic modelling. *J. Intern. Med.* 2012, 271, 142–154. [CrossRef]

17. Masoudi-Nejad, A.; Asgari, Y. Metabolic cancer biology: Structural-based analysis of cancer as a metabolic disease, new sights and opportunities for disease treatment. *Semin. Cancer Biol.* 2015, 30, 21–29. [CrossRef]

18. Kim, M.K.; Lun, D.S. Methods for integration of transcriptomic data in genome-scale metabolic models. *Comput. Struct. Biotechnol. J.* 2014, 11, 59–65. [CrossRef]

19. Blazier, A.S.; Papin, J.A. Integration of expression data in genome-scale metabolic network reconstructions. *Front. Physiol.* 2012, 3, 299. [CrossRef] [PubMed]

20. Leoncikas, V.; Wu, H.; Ward, L.T.; Kierzek, A.M.; Plant, N.J. Generation of 2,000 breast cancer metabolic landscapes reveals a poor prognosis group with active serotonin production. *Sci. Rep.* 2016, 6, 19771. [CrossRef] [PubMed]

21. Li, L.; Zhou, X.; Ching, W.K.; Wang, P. Predicting enzyme targets for cancer drugs by profiling human metabolic reactions in NCI-60 cell lines. *BMC Bioinform.* 2010, 11, 501. [CrossRef]

22. Marin de Mas, I.; Aguilar, E.; Zodda, E.; Balcells, C.; Marin, S.; Dallmann, G.; Thomson, T.M.; Papp, B.; Cascante, M. Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells. *PLoS Comput. Biol.* 2018, 14, e1005914. [CrossRef]
23. Swainston, N.; Smallbone, K.; Hefzi, H.; Dobson, P.D.; Brewer, J.; Hanscho, M.; Zielinski, D.C.; Ang, K.S.; Gardiner, N.J.; Gutierrez, J.M.; et al. Recon 2.2: From reconstruction to model of human metabolism. *Metabolomics* 2016, 12, 109. [CrossRef] [PubMed]

24. Collado-Torres, L.; Nellore, A.; Jaffe, A.E. recount workflow: Accessing over 70,000 human RNA-seq samples with Bioconductor. *F1000Res* 2017, 6, 1558. [CrossRef]

25. Luecken, M.D.; Theis, F.J. Current best practices in single-cell RNA-seq analysis: A tutorial. *Mol. Syst. Biol.* 2019, 15, e8746. [CrossRef] [PubMed]

26. Shlomi, T.; Cabili, M.N.; Herrgard, M.J.; Palsson, B.; Ruppin, E. Network-based prediction of human tissue-specific metabolism. *Nat. Biotechnol.* 2008, 26, 1003–1010. [CrossRef]

27. Gurobi Optimization, L. Gurobi Optimizer Reference Manual. 2018. Available online: https://www.gurobi.com/documentation/ (accessed on 26 October 2020)

28. Kenley, E.C.; Cho, Y. Entropy-Based Graph Clustering: Application to Biological and Social Networks. In Proceedings of the 2011 IEEE 11th International Conference on Data Mining, Vancouver, BC, Canada, 11–14 December 2011; pp. 1116–1121.

29. Zhang, Z.; Li, T.; Ding, C.; Zhang, X. Binary Matrix Factorization with Applications. In Proceedings of the Seventh IEEE International Conference on Data Mining (ICDM 2007), Omaha, NE, USA, 28–31 October 2007; pp. 391–400. [CrossRef]

30. Lee, S.; Huang, J.Z.; Hu, J. Sparse logistic principal components analysis for binary data. *Ann. Appl. Stat.* 2010, 4, 1579–1601. [CrossRef] [PubMed]

31. Li, T. A General Model for Clustering Binary Data. In Proceedings of the Eleventh ACM SIGKDD International Conference on Knowledge Discovery in Data Mining, Chicago, IL, USA, 21–24 August 2005; ACM: New York, NY, USA, 2005; pp. 188–197. [CrossRef]

32. Jack, D.L.; Paulsen, I.T.; Saier, M.H. The amino acid/polyamine/organocation (APC) superfamily of transporters specific for amino acids, polyamines and organocations. *Microbiology* 2000, 146 Pt 8, 1797–1814. [CrossRef]

33. Tseng, T.T.; Gratwick, K.S.; Kollman, J.; Park, D.; Nies, D.H.; Goffeau, A.; Saier, M.H. The RND permease superfamily: An ancient, ubiquitous and diverse family that includes human disease and development proteins. *J. Mol. Microbiol. Biotechnol.* 1999, 1, 107–125. [PubMed]

34. Zhou, Y.; Yuan, J.; Li, Z.; Wang, Z.; Cheng, D.; Du, Y.; Li, W.; Kan, Q.; Zhang, W. Genetic polymorphisms and function of the organic anion-transporting polypeptide 1A2 and its clinical relevance in drug disposition. *Pharmacology* 2015, 95, 201–208. [CrossRef]

35. Jiang, Y.; Cao, Y.; Wang, Y.; Li, W.; Liu, X.; Lv, Y.; Li, X.; Mi, J. Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis. *Theranostics* 2017, 7, 1036–1046. [CrossRef]

36. Hansson, J.; Lindgren, D.; Nilsson, H.; Johansson, E.; Johansson, M.; Gustavsson, L.; Axelson, H. Overexpression of Functional SLC6A3 in Clear Cell Renal Cell Carcinoma. *Clin. Cancer Res.* 2013, 23, 2105–2115. [CrossRef]

37. Muglia, V.F.; Prando, A. Renal cell carcinoma: Histological classification and correlation with imaging findings. *Radiol. Bras.* 2015, 48, 166–174. [CrossRef]

38. McGuire, B.B.; Fitzpatrick, J.M. Biomarkers in renal cell carcinoma. *Curr. Opin. Urol.* 2009, 19, 441–446. [CrossRef]

39. Wohlrab, C.; Phillips, E.; Dachs, G.U. Vitamin C Transporters in Cancer: Current Understanding and Gaps in Knowledge. *Front. Oncol.* 2017, 7, 74. [CrossRef]

40. Linehan, W.M.; Linehan, W.M.; Spellman, T.; Ricketts, J.; Creighton, J.; Fei, S.; Wheeler, A.D.; Murray, A.; Schmidt, L.; Vocke, D.; et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. *N. Engl. J. Med.* 2016, 374, 135–145. [PubMed]

41. Ricketts, C.J.; De Cubas, A.A.; Fan, H.; Smith, C.C.; Lang, M.; Reznik, E.; Bowlby, R.; Gibb, E.A.; Akbani, R.; Beroukhim, R.; et al. The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. *Cell. Rep.* 2018, 23, 313–326. [CrossRef]

42. Brockhausen, I. Pathways of O-glycan biosynthesis in cancer cells. *Biochim. Biophys. Acta* 1999, 1473, 67–95. [CrossRef]

43. Kandasamy, P.; Gyimesi, G.; Kanai, Y.; Hediger, M.A. Amino acid transporters revisited: New views in health and disease. *Trends. Biochem. Sci.* 2018, 43, 752–789. [CrossRef]

44. Thakkar, N.; Lockhart, A.C.; Lee, W. Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. *AAPS J.* 2015, 17, 535–545. [CrossRef]
45. Nishino, S.; Itoh, A.; Matsuoka, H.; Maeda, K.; Kamoshida, S. Immunohistochemical analysis of organic anion transporter 2 and reduced folate carrier 1 in colorectal cancer: Significance as a predictor of response to oral uracil/fluorafur plus leucovorin chemotherapy. *Mol. Clin. Oncol.* **2013**, *1*, 661–667. [PubMed]

46. Loayza-Puch, F.; Agami, R. Monitoring amino acid deficiencies in cancer. *Cell Cycle* **2016**, *15*, 2229–2230. [CrossRef] [PubMed]

47. Angione, C.; Pratwananich, N.; Lio, P. A Hybrid of Metabolic Flux Analysis and Bayesian Factor Modeling for Multitomic Temporal Pathway Activation. *ACS Synth. Biol.* **2015**, *4*, 880–889. [CrossRef] [PubMed]

48. Heinonen, M.; Osmala, M.; Mannerstrom, H.; Wallenius, J.; Kaski, S.; Rousu, J.; Lahdesmaki, H. Bayesian metabolic flux analysis reveals intracellular flux couplings. *Bioinformatics* **2019**, *35*, i548–i557. [CrossRef] [PubMed]

49. Zhu, Y.; Song, J.; Xu, Z.; Sun, J.; Zhang, Y.; Li, Y.; Ma, Y. Development of thermodynamic optimum searching (TOS) to improve the prediction accuracy of flux balance analysis. *Biotechnol. Bioeng.* **2013**, *110*, 914–923. [CrossRef] [PubMed]

50. Niittylae, T.; Chaudhuri, B.; Sauer, U.; Frommer, W.B. Comparison of quantitative metabolite imaging tools and carbon-13 techniques for fluxomics. *Methods Mol. Biol.* **2009**, *553*, 355–372.

51. Long, C.P.; Antoniewicz, M.R. High-resolution 13C metabolic flux analysis. *Nat. Protoc.* **2019**, *14*, 2856–2877. [CrossRef]

52. Hanke, T.; Noh, K.; Noack, S.; Polen, T.; Bringer, S.; Sahm, H.; Wiechert, W.; Bott, M. Combined fluxomics and transcriptomics analysis of glucose catabolism via a partially cyclic pentose phosphate pathway in Gluconobacter oxydans 621H. *Appl. Environ. Microbiol.* **2013**, *79*, 2336–2348. [CrossRef] [PubMed]

53. Daniels, W.; Bouvin, J.; Busche, T.; Ruckert, C.; Simoens, K.; Karamanou, S.; Van Mellaert, L.; Friojonsson, O.H.; Nicolai, B.; Economou, A.; et al. Transcriptomic and fluxomic changes in Streptomyces lividans producing heterologous protein. *Microb. Cell. Fact.* **2018**, *17*, 198. [CrossRef]

54. Mhamdi, H.; Bourdon, J.; Larhlimi, A.; Elloumi, M. Bayesian Integrative Modeling of Genome-Scale Metabolic and Regulatory Networks. *Informatics* **2020**, *7*, 1. [CrossRef]

55. St. John, P.C.; Strutz, J.; Broadbelt, L.J.; Tyo, K.E.J.; Bomble, Y.J. Bayesian inference of metabolic kinetics from genome-scale multomics data. *PLoS Comput. Biol.* **2019**, *15*, 1–23. [CrossRef] [PubMed]

56. Hackett, S.R.; Zanotelli, V.R.T.; Xu, W.; Goya, J.; Park, J.O.; Perlman, D.H.; Gibney, P.A.; Botstein, D.; Storey, J.D.; Rabinowitz, J.D. Systems-level analysis of mechanisms regulating yeast metabolic flux. *Science* **2016**, *354*. [CrossRef]

57. Jenni Heino, J.; Tunyan, K.; Calvetti, D.; Somersaloa, E. Bayesian flux balance analysis applied to a skeletal muscle metabolic model. *J. Theor. Biol.* **2007**, *248*, 91–110. [CrossRef] [PubMed]

58. Katz, A. G-1,6-P2, Glycolysis, and Energy Metabolism During Circulatory Occlusion in Human Skeletal Muscle. *Am. J. Physiol.* **1988**, *255*, 140–144. [CrossRef] [PubMed]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).